Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $31.00 | Overweight | Wells Fargo |
| 8/15/2025 | $43.00 | Buy | Jefferies |
| 5/19/2025 | $13.00 | Perform → Underperform | Oppenheimer |
| 12/20/2024 | $20.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/19/2024 | Outperform → Strong Buy | Raymond James | |
| 8/16/2024 | $27.00 | Outperform | Raymond James |
| 6/25/2024 | Perform | Oppenheimer |
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET. Access to this event will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the company's website for at least 30 days. About Liquidia Corporation Liquidia Corporation is a biopharmaceuti
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606 MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA),
MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor conferences. BofA Securities 2026 Health Care ConferenceDate: Wednesday, May 13, 2026 at 8:40 am PTLocation: Las Vegas, NevadaIn addition to hosting one-on-one meetings, Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business during a fireside chat beginning at 8:40 am Pacific Time. H.C. Wainwright
144 - Liquidia Corp (0001819576) (Subject)
144 - Liquidia Corp (0001819576) (Subject)
144 - Liquidia Corp (0001819576) (Subject)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00
Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00
Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form
SC 13G/A - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
SC 13D/A - Liquidia Corp (0001819576) (Subject)
MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidi
Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ
MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The